Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Covington
Teva
McKesson
AstraZeneca

Generated: March 26, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LANOXIN

« Back to Dashboard

Clinical Trials for Lanoxin

Trial ID Title Status Sponsor Phase Summary
NCT00578617 Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial Completed Duke Clinical Research Institute N/A The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up.
NCT00578617 Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial Completed St. Jude Medical N/A The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up.
NCT00578617 Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial Completed Mayo Clinic N/A The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up.
NCT00831506 Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects Completed Medivation, Inc. Phase 1 This study has been designed to confirm, in healthy subjects, the lack of a clinically important pharmacokinetic interaction between Dimebon, at the proposed maximum commercial dose of 20 mg TID (administered every 8 hours), and digoxin (Lanoxin®) 0.125 mg QD, a sensitive P-gp substrate recommended by FDA.
NCT00831506 Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects Completed Pfizer Phase 1 This study has been designed to confirm, in healthy subjects, the lack of a clinically important pharmacokinetic interaction between Dimebon, at the proposed maximum commercial dose of 20 mg TID (administered every 8 hours), and digoxin (Lanoxin®) 0.125 mg QD, a sensitive P-gp substrate recommended by FDA.
NCT01047748 A Trial of Digoxin Before Second-Trimester Abortion Completed Society of Family Planning N/A The purpose of our study is to determine the optimum route for the injection of digoxin prior to second-trimester surgical abortion.
NCT01047748 A Trial of Digoxin Before Second-Trimester Abortion Completed White, Katharine O'Connell, M.D., M.P.H. N/A The purpose of our study is to determine the optimum route for the injection of digoxin prior to second-trimester surgical abortion.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Lanoxin

Condition Name

Condition Name for Lanoxin
Intervention Trials
Healthy 3
Arrhythmia 1
Melanoma 1
Alzheimer Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Lanoxin
Intervention Trials
Melanoma 1
Huntington Disease 1
Alzheimer Disease 1
Atrial Fibrillation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Lanoxin

Trials by Country

Trials by Country for Lanoxin
Location Trials
United States 14
Sweden 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Lanoxin
Location Trials
Texas 2
California 2
Connecticut 1
Utah 1
Pennsylvania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Lanoxin

Clinical Trial Phase

Clinical Trial Phase for Lanoxin
Clinical Trial Phase Trials
Phase 1 5
N/A 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Lanoxin
Clinical Trial Phase Trials
Completed 6
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Lanoxin

Sponsor Name

Sponsor Name for Lanoxin
Sponsor Trials
University of Texas Southwestern Medical Center 1
Medivation, Inc. 1
Lexicon Pharmaceuticals 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Lanoxin
Sponsor Trials
Industry 6
Other 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
UBS
Covington
Argus Health
Healthtrust
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.